Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Trautmann-Grill, K. [1 ]
Lonial, S. [2 ]
Nooka, A. K. [2 ]
Thulasi, P. [3 ]
Badros, A. Z. [4 ]
Jeng, B. H. [4 ]
Callander, N. S. [5 ]
Sborov, D. [6 ]
Zaugg, B. E. [7 ]
Popat, R. [8 ]
Degli, Esposti S. [9 ,10 ]
Baron, J. [11 ]
Doherty, A. [12 ]
Lewis, E. [13 ]
Opalinska, J. [11 ]
Paka, P. [11 ]
Piontek, T. [11 ]
Gupta, I [11 ]
Farooq, A., V [14 ]
Jakubowiak, A. [14 ]
机构：
[1] Univ Klinkum Carl Gustav, Dresden, Germany
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Emory Univ, Emory Eye Ctr, Atlanta, GA 30322 USA
[4] Univ Maryland, Sch Med, Baltimore, MD USA
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[7] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA
[8] Univ Coll London Hosp, NHS Fdn Trust, London, England
[9] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[10] UCL Inst Ophthalmol, London, England
[11] GlaxoSmithKline, Providence, RI USA
[12] GlaxoSmithKline, Collegeville, MN USA
[13] GlaxoSmithKline, Res Triangle Pk, NC USA
[14] Univ Chicago, Med Ctr, Chicago, IL USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep271
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [1] Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Baron, January
    Doherty, Allison
    Lewis, Eric
    Opalinska, Joanna
    Paka, Prani
    Piontek, Trisha
    Gupta, Ira
    Farooq, Asim V.
    Jakubowiak, Andrzej
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S419 - S419
  • [2] Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma
    Lonial, Sagar
    Nooka, Ajay
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Baron, January
    Doherty, Allison
    Lewis, Eric
    Opalinska, Joanna
    Paka, Prani
    Piontek, Trisha
    Gupta, Ira
    Farooq, Asim V.
    Jakubowiak, Andrzej
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S149 - S150
  • [3] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Farooq, Asim
    Thulasi, Praneetha
    Lonial, Sagar
    Jakubowiak, Andrzej
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Womersley, Lynsey
    Gupta, Ira
    Esposti, Simona Degli
    BLOOD, 2020, 136
  • [4] Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
    Eliason, Laurie
    Correll, Julia
    Martin, Mona
    Cardellino, Anna
    Opalinska, Joanna
    Piontek, Trisha
    Gorsh, Boris
    Sapra, Sandhya
    Popat, Rakesh
    BLOOD, 2020, 136
  • [5] Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Nooka, Ajay
    Lee, Hans C.
    Badros, Ashraf Z.
    Voorhees, Peter
    Hultcrantz, Malin
    Karlin, Lionel
    Arnulf, Bertrand
    Richardson, Paul G.
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    Lonial, Sagar
    BLOOD, 2020, 136
  • [6] DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies
    Weisel, K.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Vorhees, P.
    Opalinska, J.
    Hoos, A.
    Zhi, E.
    Baron, J.
    Piontek, T.
    Jewell, R.
    Gupta, I
    Cohen, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 109 - 110
  • [7] DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Popat, Rakesh
    Lonial, Sagar
    Voorhees, Peter M.
    Degli Esposti, Simona
    Gupta, Ira
    Opalinska, Joanna
    Sapra, Sandhya
    Gorsh, Boris
    He, Zangdong
    Kleinman, David M.
    Schaumberg, Debra
    Loubert, Angely
    Meunier, Juliette
    Regnault, Antoine
    Eliason, Laurie
    BLOOD, 2020, 136
  • [8] Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/ Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante-Barrigon, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Greil, Richard
    Melchardt, Thomas
    Antonioli, Elisabetta
    Schjesvold, Fredrik
    Lysen, Anna
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    Mouro, Jorge
    D'Estrube, Tim
    Fry, Mark
    Byrne, Julie
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S277 - S278
  • [9] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Degli Esposti, Simona
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
  • [10] Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
    Nooka, Ajay K.
    Cohen, Adam
    Lee, Hans C.
    Badros, Ashraf Z.
    Suvannasankha, Attaya
    Callander, Natalie
    Abdallah, Al-Ola
    Trudel, Suzanne
    Chari, Ajai
    Libby, Edward
    Chaudhry, Maria
    Hultcrantz, Malin
    Kortuem, Martin
    Richardson, Paul G.
    Popat, Rakesh
    Sborov, Douglas W.
    Hakim, Shawn
    Lewis, Eric
    Bhushan, Bharat
    Gorsh, Boris
    Gupta, Ira
    Opalinska, Joanna
    Lonial, Sagar
    BLOOD, 2022, 140 : 7301 - 7303
12345